Arimidex Observational: Reason for and Effect of Change From Tamoxifen
NCT00246961 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2007-10-12
Summary
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AstraZeneca The Netherlands Medical Director, MD · AstraZeneca
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-07-31
Countries
- Netherlands
Study Locations
More Related Trials
-
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
NCT00286117 ·Status: COMPLETED ·Phase: PHASE3
-
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
NCT00301457 ·Status: COMPLETED ·Phase: PHASE3
-
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
NCT00232661 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
NCT00692289 ·Status: COMPLETED
-
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
NCT00309491 ·Status: COMPLETED ·Phase: PHASE3
-
Tamoxifen in Treating Women With Breast Cancer
NCT00003678 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Arimidex and Radiotherapy Sequencing
NCT01402193 ·Status: UNKNOWN ·Phase: PHASE3
-
Liver Safety Under Upfront Arimidex vs Tamoxifen
NCT00537771 ·Status: COMPLETED ·Phase: PHASE4
-
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
NCT00032136 ·Status: COMPLETED ·Phase: PHASE3
-
Retrospective Survey of Bone Fracture in Patients With Arimidex 1mg
NCT00859560 ·Status: COMPLETED
-
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
NCT00291759 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
NCT00002460 ·Status: UNKNOWN ·Phase: PHASE3
-
Therapeutic Dose Monitoring (TDM) of Tamoxifen
NCT05133674 ·Status: UNKNOWN ·Phase: PHASE2
-
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
NCT00003418 ·Status: UNKNOWN ·Phase: PHASE3
-
Arimidex Therapy Compliance Electronic Monitoring System
NCT00936442 ·Status: COMPLETED
-
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
NCT00038467 ·Status: COMPLETED ·Phase: PHASE3
-
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
NCT00638391 ·Status: COMPLETED
-
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
NCT00784888 ·Status: COMPLETED
-
ATAC - Quality of Life Sub-Protocol
NCT00784680 ·Status: COMPLETED ·Phase: PHASE3
-
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
NCT00253539 ·Status: COMPLETED ·Phase: PHASE2
-
ATAC - Arimidex, Tamoxifen Alone or in Combination
NCT00849030 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
NCT00036270 ·Status: COMPLETED ·Phase: PHASE3
-
Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)
NCT00857012 ·Status: COMPLETED
-
Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users
NCT01579734 ·Status: UNKNOWN ·Phase: PHASE3
-
Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer
NCT00003016 ·Status: UNKNOWN ·Phase: PHASE3